BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24778183)

  • 1. Gossypol increases expression of the pro-apoptotic BH3-only protein NOXA through a novel mechanism involving phospholipase A2, cytoplasmic calcium, and endoplasmic reticulum stress.
    Soderquist RS; Danilov AV; Eastman A
    J Biol Chem; 2014 Jun; 289(23):16190-9. PubMed ID: 24778183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA.
    Soderquist R; Pletnev AA; Danilov AV; Eastman A
    Apoptosis; 2014 Jan; 19(1):201-9. PubMed ID: 24072590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.
    Albershardt TC; Salerni BL; Soderquist RS; Bates DJ; Pletnev AA; Kisselev AF; Eastman A
    J Biol Chem; 2011 Jul; 286(28):24882-95. PubMed ID: 21628457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
    S Soderquist R; Eastman A
    Mol Cancer Ther; 2016 Sep; 15(9):2011-7. PubMed ID: 27535975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477.
    Mallick DJ; Soderquist RS; Bates D; Eastman A
    Cell Death Dis; 2019 Feb; 10(3):185. PubMed ID: 30796196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
    Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S
    Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
    Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E
    Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells.
    Zhu H; Yang W; He LJ; Ding WJ; Zheng L; Liao SD; Huang P; Lu W; He QJ; Yang B
    PLoS One; 2012; 7(12):e52333. PubMed ID: 23284992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
    Hauck P; Chao BH; Litz J; Krystal GW
    Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737.
    Bates DJ; Danilov AV; Lowrey CH; Eastman A
    Mol Cancer Ther; 2013 Aug; 12(8):1504-14. PubMed ID: 23723123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo.
    Soderquist R; Bates DJ; Danilov AV; Eastman A
    Leukemia; 2013 Nov; 27(11):2262-4. PubMed ID: 23640104
    [No Abstract]   [Full Text] [Related]  

  • 12. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
    Meng Y; Tang W; Dai Y; Wu X; Liu M; Ji Q; Ji M; Pienta K; Lawrence T; Xu L
    Mol Cancer Ther; 2008 Jul; 7(7):2192-202. PubMed ID: 18645028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA.
    Mallick DJ; Eastman A
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
    Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
    Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Noxa-like BH3 mimetics for apoptosis-based therapeutic strategy in chronic lymphocytic leukemia.
    Billard C
    Mol Cancer Res; 2012 Jun; 10(6):673-6. PubMed ID: 22466256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
    Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD
    Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cap-translation inhibitor, 4EGI-1, restores sensitivity to ABT-737 apoptosis through cap-dependent and -independent mechanisms in chronic lymphocytic leukemia.
    Willimott S; Beck D; Ahearne MJ; Adams VC; Wagner SD
    Clin Cancer Res; 2013 Jun; 19(12):3212-23. PubMed ID: 23633452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
    Anderson MA; Deng J; Seymour JF; Tam C; Kim SY; Fein J; Yu L; Brown JR; Westerman D; Si EG; Majewski IJ; Segal D; Heitner Enschede SL; Huang DC; Davids MS; Letai A; Roberts AW
    Blood; 2016 Jun; 127(25):3215-24. PubMed ID: 27069256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.
    Lestini BJ; Goldsmith KC; Fluchel MN; Liu X; Chen NL; Goyal B; Pawel BR; Hogarty MD
    Cancer Biol Ther; 2009 Aug; 8(16):1587-95. PubMed ID: 19556859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA.
    Subramanian A; Andronache A; Li YC; Wade M
    Oncotarget; 2016 Mar; 7(13):15986-6002. PubMed ID: 26910119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.